Back

Improved electrical performance/stability of a novel active fixation coronary sinus lead compared to passive fixation leads: a multi-centre study

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 6 - Cardiac resynchronisation therapy Cardiac Resynchronisation Therapy (CRT) ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Dimitrios Gerontitis

IASO General Clinic, Maroussi-Athens (Greece)

9 More presentations in this session

Presentation thumbnail
Utility of late iodine enhancement computed tomography with image subtraction in the evaluation of cardiac resynchronization therapy response
Doctor T. Pezel (Paris, FR)
Abstract
Presentation thumbnail
One-year outcomes of heart failure patients undergoing cardiac resynchronization therapy using adaptivCRT algorithm
Doctor S. Briongos Figuero (Madrid, ES)
Abstract
Presentation thumbnail
Cardiac resynchronization therapy with a single left ventricular septal pacing electrode: acute hemodynamic and electrophysiological effects
Ms F. Salden (Maastricht, NL)
Abstract
Presentation thumbnail
Incremental hazard associated with the degree of advanced intaratrial block in cardiac resynchronization therapy treated heart failure patients
Doctor J. Jacobsson (Lund, SE)
Abstract Slides
Presentation thumbnail
Left ventricular wall thickness measured with computed tomography stratifies the response to cardiac resynchronization therapy in patients with non-ischemic cardiomyopathy.
Doctor V. Galand (Rennes, FR)
Abstract

Access the full session

Session thumbnail
Poster Session 6 - Cardiac resynchronisation therapy

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Conduction system pacing in the current treatment of HFrEF patients
thumbnail
Congress Presentation
Device therapy: how to identify responders?
thumbnail
Congress Presentation
Cardiac resynchronisation therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources